ArticleMedeniyet medical journal2022
Post-COVID-19 Dermatomyositis: A Delayed Reaction That Evades Early Detection.
Article in Medeniyet medical journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
- Prevalence of cutaneous manifestations and myositis-specific antibodies in COVID-19 patients and Anti-PL7 antibodies association with pulmonary radiological severity: A retrospective study.International journal of immunopathology and pharmacologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatomyositis (DM) is a rare autoimmune disease that causes symmetrical and predominantly proximal muscle weakness in the limbs and typical skin lesions. Its prevalence increased during the coronavirus disease-2019 (COVID-19) pandemic. Viral infections may cause autoimmunity and trigger the pathogenesis of myositis. We present the case of a man with a long history of myalgia and muscle weakness, who was initially diagnosed with post-COVID-19 myalgia and subsequently developed progressive muscle weakness. Biochemical and muscle biopsy results confirmed DM. The patient responded favorably to the course of steroid treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.